Lancashire &
South Cumbria
Medicines
Management
Group

LSCMMG Recurrent UTI Prophylactic Antibiotic Pathway

Version 1.2- April 2024

Introduction



VERSION CONTROL		
Version	Date	Amendments made
1.0	November 2020	New guideline.
1.1	December 2023	Reference to legacy formularies added.
1.2		Pathway was updated following discussions with the local AMR group. Nitrofurantoin safety information added.

Contents


1. LSCMMG Recurrent UTI Prophylactic Antibiotic Pathway

 $\hbox{@Midlands and Lancashire Commissioning Support Unit, 2023.}\\$

The information contained herein may be superseded in due course. All rights reserved. Produced for use by the NHS, no reproduction by or for commercial organisations, or for commercial purposes, is allowed without express written permission.

Midlands and Lancashire Commissioning Support Unit, **Jubilee House,** Lancashire Business Park, Leyland, PR26 6TR **Tel:** 01772 644 400 | www.midlandsandlancashirecsu.nhs.uk

LSCMMG Recurrent UTI Prophylactic Antibiotic Pathway



guideline 112

Further information

Nitrofurantoin safety information

The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a reminder about the risks of pulmonary and hepatic adverse reactions associated with Nitrofurantoin. This follows a fatality report of a patient who developed acute pulmonary damage and respiratory failure after a 10-day course of Nitrofurantoin for urinary-tract infection treatment.

Key points from the MHRA advice are:

- Healthcare professionals should increase vigilance for acute pulmonary reactions in the first week
 of treatment.
- Patients on long-term therapy, especially the elderly, should be closely monitored for new or worsening respiratory symptoms.
- Treatment should be discontinued immediately if new or worsening symptoms of pulmonary damage occur.
- Caution should be exercised when prescribing to patients with pulmonary disease which may
 mask the signs and symptoms of adverse reactions.
- Healthcare professionals should be vigilant for signs and symptoms of hepatic dysfunction, especially with long-term therapy, and periodically monitor for signs and changes in biochemical tests that would indicate hepatitis or liver injury.
- Caution should be used when prescribing to patients with hepatic dysfunction which may mask the signs and symptoms of adverse reactions.

Patients and their carers are advised to seek immediate medical advice if symptoms of pulmonary or hepatic adverse reactions develop.

The local antimicrobial stewardship committee have recommended that the following baseline test should be completed before commencing nitrofurantoin long-term and repeated three-six monthly thereafter:

LFTs,
Renal function,
Oxygen saturation,
Chest x-ray,
Dyspnoea (using the mMRC dyspnoea score)